Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial

Aaron J. Grossberg; Krishan R. Jethwa; Susannah G. Ellsworth

doi:10.1001/jamaoncol.2022.6135

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial

Aaron J. Grossberg, Krishan R. Jethwa, Susannah G. Ellsworth

Knight Cancer Prevention and Control Program

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	275
Number of pages	1
Journal	JAMA Oncology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1001/jamaoncol.2022.6135
State	Published - Feb 16 2023

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2022.6135

Cite this

@article{03d7d29450f14cefa373488ac3b2e1a0,

title = "Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial",

author = "Grossberg, {Aaron J.} and Jethwa, {Krishan R.} and Ellsworth, {Susannah G.}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Grossberg reported receiving grants from National Cancer Institute and American Association for Cancer Research and personal fees from Endevica Bio. Dr Jethwa reported receiving personal fees (honoraria) from RadOncQuestions.com, LLC. No other disclosures were reported. ",

year = "2023",

month = feb,

day = "16",

doi = "10.1001/jamaoncol.2022.6135",

language = "English (US)",

volume = "9",

pages = "275",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial

AU - Grossberg, Aaron J.

AU - Jethwa, Krishan R.

AU - Ellsworth, Susannah G.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Grossberg reported receiving grants from National Cancer Institute and American Association for Cancer Research and personal fees from Endevica Bio. Dr Jethwa reported receiving personal fees (honoraria) from RadOncQuestions.com, LLC. No other disclosures were reported.

PY - 2023/2/16

Y1 - 2023/2/16

UR - http://www.scopus.com/inward/record.url?scp=85148306913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85148306913&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2022.6135

DO - 10.1001/jamaoncol.2022.6135

M3 - Letter

C2 - 36454560

AN - SCOPUS:85148306913

SN - 2374-2437

VL - 9

SP - 275

JO - JAMA Oncology

JF - JAMA Oncology

IS - 2

ER -

Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients with Borderline Resectable Pancreatic Cancer - The A021501 Trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this